Spectrum Pharmaceuticals, Inc. (SPPI)


Stock Price Forecast

Aug. 1, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Spectrum Pharmaceuticals, Inc. chart...

About the Company

spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.

Exchange

NASDAQ

Website

https://www.sppirx.com/

$31M

Total Revenue

259

Employees

$211M

Market Capitalization

-2.59

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SPPI News

Spectrum Pharma Sells Marketed Portfolio in a Deal That Could Reach $300 Million

5y ago, source: TheStreet.com

Spectrum Pharmaceuticals Inc. (SPPI) popped Thursday after the company announced that it was selling its marketed portfolio of seven Food and Drug Administration-approved products to Acrotech ...

Why Spectrum Fell on Beleodaq Approval but Will Rocket on Melphalan Approval

9y ago, source: TheStreet.com

Now let's look at TheStreet Ratings' take on this stock. TheStreet Ratings team rates SPECTRUM PHARMACEUTICALS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about ...

SHAREHOLDER ALERT: Potential Recovery for Assertio Holdings, Inc. (ASRT) Investors

18d ago, source: TipRanks on MSN

A class action securities lawsuit was filed against Assertio Holdings, Inc. (ASRT) that seeks to recover losses of Assertio Holdings shareholders who were adversely affected by alleged securities ...

Assertio Scoops Up Spectrum Pharma In $248M Stock Deal

10mon ago, source: Hosted on MSN

Assertio Holdings Inc (NASDAQ: ASRT) will acquire Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) in an all-stock and contingent value rights (CVR) transaction. Under the terms of the agreement ...

Assertio 48 Hour Deadline Alert

16d ago, source: Business Insider

In July 2023, Assertio acquired Spectrum Pharmaceuticals, Inc. ("Spectrum"), a biopharmaceutical company focused on novel and targeted oncology, along with Spectrum's injection asset Rolvedon (the ...

Assertio Deadline Alert

28d ago, source: Stockhouse

In July 2023, Assertio acquired Spectrum Pharmaceuticals, Inc. ("Spectrum"), a biopharmaceutical company focused on novel and targeted oncology, along with Spectrum's injection asset Rolvedon (the ...

Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction

1mon ago, source: ADVFN

today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Nasdaq: SPPI), a biopharmaceutical company focused on novel and targeted oncology.

Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical

19h ago, source:

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $92.75, along ...

Deciphera Pharmaceuticals, Inc.

2mon ago, source: CNN

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company ... The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that ...

Spectrum Pharmaceuticals In Deal With Viropro For Cancer Drug

29d ago, source: ADVFN

Spectrum Pharmaceuticals Inc. (SPPI) signed a deal with biopharmaceutical company Viropro Inc. (VPRO) to develop a biosimilar version of Swiss pharmaceutical giant Roche Holding AG's (RHHBY ...

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

22h ago, source: Yahoo Finance

STATEN ISLAND, N.Y., March 18, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP ... Dr. Kevin Garey presented on behalf of the Company at ID Week with selective spectrum of activity data ...

Q4 2023 Acurx Pharmaceuticals Inc Earnings Call

7h ago, source:

Michael Okunewitch; Senior Research Analyst; Maxim Group LLC, Research Division ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...